Fractional CO₂ Laser: From Skin Rejuvenation to Vulvo-Vaginal Reshaping

Maurizio Filippini, MD;1 Ester Del Duca, MD;2 Francesca Negosanti, MD;3,4 Diletta Bonciani, MD;5 Luca Negosanti, MD;6 Mario Sannino, MD;4 Giovanni Cannarozzo, MD;4 and Steven Paul Nisticò, MD;4,7

Abstract

Background: The CO₂ laser has become the gold standard treatment in dermatologic surgery for the treatment of a large number of skin and mucosal lesions. The introduction of the fractional micro-ablative technology represented an integration to the ablative resurfacing technique, reducing the healing time and the side effects. Objective: Vaginal rejuvenation performed with this technique is a minimally invasive procedure that stimulates internal tissues of the female lower genital tract to regenerate the mucosa, improving tissue trophism and restoring the correct functionality. Methods: In our experience, 386 menopausal women affected with vulvo-vaginal atrophy (VVA) were treated with three sessions of fractional micro-ablative CO₂ laser. Results: After three treatments, patients reported a complete improvement of the symptoms (59.94% dryness, 56.26% burning sensation, 48.75% dyspareunia, 56.37% itch, 73.15% soreness, and 48.79% vaginal introitus pain). Conclusions: Fractional micro-ablative CO₂ laser seems to reduce symptoms related to vaginal atrophy. The beneficial effects were reported just after the first session and confirmed 12 months after the last session.

Keywords: vulvo-vaginal atrophy (VVA), genitourinary syndrome, vulvo-vaginal rejuvenation, fractional micro-ablative laser CO₂ technology

Introduction

In the previous 30 years, CO₂ laser has become the gold standard treatment in dermatologic surgery for the treatment of a large number of skin and mucosal lesions. Considering the increasing demands regarding aesthetic treatment, laser technology has been successfully used in the past 10 years to treat aesthetic diseases such as acne scars, and to improve photo and chrono-aging facial effects.¹

The introduction of the fractional micro-ablative technology represented an integration to the ablative resurfacing technique, reducing healing time and side effects. Technological research gives us the possibility to choose from various kinds of pulses with different ablation and coagulation characteristics, with consequent faster healing, no scarring, and the stimulation of new collagen production.

Due to the effects on tissues rejuvenation, many studies have been carried out since 2008 on the application of CO₂ laser treatment on vaginal tissue. Vaginal rejuvenation is a quick and painless minimally invasive procedure that stimulates internal tissues of the female lower genital tract to regenerate the mucosa, improving tissue trophism and restoring the correct functionality.²

The progressive reduction in estrogen production during the climacteric causes many metabolic and tissue changes, above all in the genital tract, which is very sensitive to sex hormones.²,³

In particular, vaginal walls become thinner, lose their elasticity and the typical roation of the fertile period. The entire vagina gradually becomes tighter and shorter; the vaginal epithelium becomes brittle, often bleeding even after minimal trauma. Similarly, the vulvar area became atrophic and more vulnerable.⁴

Typical symptoms of vulvo-vaginal atrophy (VVA) are vaginal dryness, itching, burning, soreness, dysuria, dyspareunia, incontinence, nycturia, and frequent cystitis.⁵,⁶

1Department of Obstetric and Gynecology, Hospital State of Republic of San Marino, San Marino, Republic of San Marino.
2Department of Dermatology, University of Rome Tor Vergata, Rome, Italy.
3Dermatology Center srl, Bologna, Italy.
4“Laser in Dermatology,” University of Rome Tor Vergata, Rome, Italy.
5Section of Dermatology, Department of Surgery and Translational Medicine, University of Florence, Ospedale “Piero Palagi,” Florence, Italy.
6Division of Plastic Surgery, S.Orsola-Malpighi University Hospital Bologna, Bologna, Italy.
7Dermatology Department of Health Sciences, “Magna Grecia” University of Catanzaro, Catanzaro, Italy.
VVA gets gradually worse over the years and certainly has an important impact on the patients’ quality of life. Many treatment protocols have been proposed over the past few years to improve VVA symptoms, such as non-hormonal drugs in mild cases and topical or systemic hormonal therapy in medium-to-severe disease activity. The systemic treatment could significantly improve the symptoms, but sometimes there are many contraindications and side effects. Moreover, the symptoms reappear after these therapies are interrupted.

In a study, conducted by Gaspar et al., the vaginal epithelium of 92 patients was treated with micro-fractional CO2 laser, combined with platelet-rich plasma, achieving great results in terms of improving VVA; the results were evaluated by vaginal biopsy performed both before and after treatment, demonstrating improvement in all three layers of the vaginal epithelium.

A similar study, conducted in 2013 by Salvatore et al., showed an improvement of VVA symptoms and VH1 scores after the 12-week follow-up.

Another recent and interesting application of CO2 laser is for the treatment of vulvar lichen sclerosus atrophicus (LSA). LSA is a chronic skin disease with unknown etiology that involves the external genitalia. Most of the patients are postmenopausal women, but this pathology could also affect men and children.

Patients reported the same symptoms linked to vaginal atrophy and significant symptoms related to vulvar involvement.

The application of laser therapy to induce a vaginal rejuvenation can help women affected by LSA eliminate these symptoms and, thus, significantly improve their quality of life.

Materials and Methods

Patient population

In our study, which took place from January 2013 to January 2015, we enrolled 386 menopausal patients (age range, 48–56 years old) (Table 1), with symptoms due to the vaginal atrophy (i.e., dryness, itching, burning, dyspareunia) and not after hormone therapy. Sixty-three were also affected by LSA. Infection investigations in all women were negative.

All patients filled in a visual analog scale questionnaire; before the first and after the second and third treatment, they had to indicate a value from 1 to 10 (where 1 meant no symptoms and 10 meant the maximum effect of the symptoms) about laxity symptoms, vaginal dryness, irritation-burning, and dyspareunia.

Vaginal laser resurfacing

The CO2 laser has a wavelength of 10,600 nm and uses a mixture of CO2, N, and He as active medium. Its target is intra- and extracellular water, which makes up 77% of the skin. The effect is a very high-energy absorption and minimal tissue penetration; also, it seals small nerve endings with pain reduction of the lymphatic vessels and with edema reduction of blood vessels with a hemostatic effect.

A new device, called SmartXide² (DEKA, Florence, Italy), introduces the use of the Vulvo-Vaginal Laser Reshaping procedure, which supplies energy with a dedicated pulse shape, called D-Pulse, derived from dermatological experience, but takes into account the peculiarities of the vaginal epithelium. The initial part of the D-Pulse involves constant and high peak power for rapid and painless superficial removal of the epithelial component of the atrophic mucosa that is characterized as having a low water content. A second variable part, with a lower peak power and a longer emission time, allows the laser energy to penetrate into the mucosa and stimulates it properly at depth.

The Stack mode also provides precise control of the vaporization depth in the skin and the thermal action. This technology delivers a number of successive pulses in the same point, from one to five, leading to a reduction of side effects.

Treatment

Gynecological evaluation was performed before treatment to assess the level of atrophy and subjective symptoms, to exclude prolapse of the pelvic organs that cannot be greater than the second degree, to rule out infections, and to perform a Pap test, which must be negative.

The CO2 laser (SmartXide² V²LR, Monalisa Touch; DEKA) was set with a DOT (micro-ablative zone) power of 40 W, a dwell time of 1000 µsec, a DOT spacing of 1000 µm, and a Stack of 2. The laser probe was inserted into the vagina without speculum and without using lubricants or topical anesthetics. Patients reported only mild discomfort.

### Table 1. Patient Age Characteristics

<table>
<thead>
<tr>
<th>Patient age (years)</th>
<th>No. of patients (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>48–50</td>
<td>44 (12)</td>
</tr>
<tr>
<td>51–60</td>
<td>245 (64)</td>
</tr>
<tr>
<td>61–70</td>
<td>75 (20)</td>
</tr>
<tr>
<td>&gt;70</td>
<td>22 (6)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Pulse</th>
<th>Power (watt)</th>
<th>Dwell time (msec)</th>
<th>Dot spacing (µm)</th>
<th>Stack</th>
</tr>
</thead>
<tbody>
<tr>
<td>Endovaginal</td>
<td>DP</td>
<td>40</td>
<td>1000</td>
<td>1000</td>
</tr>
<tr>
<td>Vulva</td>
<td>DP</td>
<td>30</td>
<td>1000</td>
<td>1000</td>
</tr>
</tbody>
</table>

FIG. 1. (a, b) The vaginal and vulvar appearance immediately after fractional CO2 laser treatment.
during the insertion of the probe, but no pain during treat-
ment. The treatment takes only a few minutes.

The treatment was then used on the vaginal introitus and
vulva by using a fractioned scanner handpiece (SmartXide\textsuperscript{2} V\textsuperscript{2}LR, Vulvar Probe; DEKA). The laser was set to a DOT power of 30 W, a dwell time of 1000 µsec, a DOT spacing of 1000 µm, and a Stack of 1 (Table 2 and Fig. 1a, b).

Unlike vaginal treatment, which is considered painless, the vulvar treatment is quite painful. After treatment, pa-
tients were recommended to use a moisturizing cream and
re-epithelializing eggs. Hot baths and sexual activity were
not recommended for 24 h.

Results

A total of 386 patients were treated from January 2013 to
January 2015.

Although the protocol involved three laser applications,
many patients began to see an improvement already after the
first treatment, especially in patients with just vaginal
symptoms, due to vaginal atrophy, without dyspareunia and
LSA. (Fig. 2a, b)

The main reported side effect experienced during treat-
ment was discomfort during the insertion of the probe, minimum blood–serum secretions for 1–2 days, and mild
burning for 1–2 h after treatment. No pain during treatment
was reported in 764 of the 1158 total applications (Table 3).

<table>
<thead>
<tr>
<th>Side effects during treatment</th>
<th>n (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>None</td>
<td>764 (66)</td>
</tr>
<tr>
<td>Burn sensation</td>
<td>127 (11)</td>
</tr>
<tr>
<td>Bother during the handpiece</td>
<td>70 (6)</td>
</tr>
<tr>
<td>Pain during handpiece move-</td>
<td>58 (5)</td>
</tr>
<tr>
<td>mental</td>
<td></td>
</tr>
<tr>
<td>Vulvar introitus pain</td>
<td>58 (5)</td>
</tr>
<tr>
<td>Vulvar introitus burn</td>
<td>46 (4)</td>
</tr>
<tr>
<td>Vulvar pain</td>
<td>35 (3)</td>
</tr>
</tbody>
</table>

After three treatments, patients reported a complete im-
provement of the symptoms (59.94% dryness, 56.26% burn
sensation, 48.75% dyspareunia, 56.37% itch, 73.15% soro-
ness, and 48.79% vaginal introitus pain) (Table 4).

After the first session, patients already reported feeling
lubrication similar to that before menopause; had an
improvement in the burning, discomfort, itching, and dryness
symptoms; and were again able to have painless and satis-
factory sex. Half of the patients treated reported a good
improvement in the urinary symptoms after treatment (ur-
geney, dysuria, incontinence, cystitis). This aspect was not
considered in the questionnaire, but it was spontaneously
reported by the patients.

Discussion

During their lifetime, 76% of women report a decreased
genital sensation with impaired sexual function and psy-
chological discomfort.\textsuperscript{15,16} Several methods were reported
to induce a vaginal rejuvenation, both surgical and nonsur-
gical.

The aim of surgery is to treat aesthetic problems, such as
hypertrophied labia minora, redundant labia majora, or hy-
pertrophic clitoral hood folds, as well as functional prob-
lems such as laxity or widened vagina.

The most commonly used procedures were labioplasty,
reduction of the clitoral hood, vaginoplasty, and perineo-
plasty. The use of synthetic or autologous materials, such as
lipofilling, was also described for treating vaginal widening,
but this procedure was linked with the risk of infection,
which can then lead to several problems.

This technique reported good outcomes, with a fairly low
incidence of complications. The reported techniques tried to
restore the anatomy of the vagina, reducing the widening
that occurs during a woman’s lifetime. The main problem is
that these procedures cannot be used on vaginal atrophy
linked to menopause or pathologic conditions, such as LSA.

In these cases, a true vaginal rejuvenation needs to occur
to restore vaginal function, improving sexual activity, re-
ducing the symptoms, and, thus, improving the patient’s
quality of life. The introduction of laser treatment in this
field seems to be the best method to obtain all these
results.\textsuperscript{16}

Our experience demonstrated that fractional micro-ablative
CO\textsubscript{2} laser is useful for treating the vaginal epithelium. The
use of the fractional micro-ablative CO\textsubscript{2} laser on the vaginal
mucosa was immediately associated with initial tissue re-
modeling, which leads to the foundation of its clinical ap-
plication. It also allows us to contemplate promising results as
previously described in many areas of the human body, such

![FIG. 2. (a, b) Picture of hypertrophic vulvar dystrophy: immediately after the first treatment (left) and 1 month after the third treatment (right). There is an evident improvement of the vulvar epithelium as well as a marked regression of the itchy symptoms.](image)
as the skin on the face, chest, and neck and in animal models, including the production of new collagen and other components of the extracellular matrix. The mechanism of these changes was recently proven.\textsuperscript{17}

The vaginal epithelium is characterized by the absence of keratin and the presence of a high water content. Tissue damage caused by the micro-ablations and heating of the CO\textsubscript{2} laser stimulates fibrocytes to return to being productive fibroblasts that can restore the correct composition of collagen fibers within the amorphous substance with adequate water content.

The effects of the fractional CO\textsubscript{2} laser on the mucosa can be summarized in a central zone of vaporization, an intermediate zone characterized by denaturation and contraction of the collagen fibers, which creates a thermal barrier for the underlying mucosa, and a peripheral zone of hyperthermia. In this latter area, the heat activates the heat shock proteins, in particular HSP 43-47-70. These proteins induce a local increase in different cytokines: transforming growth factor-A, basic fibroblast growth factor, epidermal growth factor, platelet-derived growth factor and vascular endothelial growth factor, stimulating matrix proteins such as collagen, angiogenic activity with endothelial cell migration and proliferation, re-epithelization, regulating neo-angiogenesis, and activating fibroblasts to produce new collagen and other components of the extracellular matrix. Using a polarized light, a layer of small collagen fibers generated by the denatured collagen can be highlighted. So the laser also works at depth without causing irreversible damage. In fact, the fibers are of small caliber and intact.\textsuperscript{18}

The final effect is to restore the correct permeability to the connective tissue. The increase in nutrients that reach the mucosa improves vaginal wall turgor; the hydration reduces itching and burning, increasing vaginal transudate that decreases dryness and dyspareunia and the recovery of mucosa tropism, with an increase of intracellular glycogen, leading to colonization by lactobacilli and a decrease in vaginal pH.

Histological studies performed 1 month after a single laser treatment show that the vaginal mucosa had a significantly increased thickness, with detachment on the cell surface and increased glycogen. The improvement reported in urinary symptoms cannot be easily explained and no bibliographic references were present, but they were largely reported in our series. The side effects reported during treatment and the very low incidence of complications, which spontaneously disappeared, led us to consider that the laser treatment is safe.

We have shown the effects of fractional micro-ablative CO\textsubscript{2} laser treatment in a large series of patients. The side effects reported by patients were very low, and the positive results were confirmed by all the patients.

To face the possible side effects and to ensure a multidisciplinary approach, gynecology and dermatology should be the specialties with legal responsibility for the procedure. Moreover, a careful selection of patients and a strict follow-up are crucial to manage complications.

Conclusions

The fractional micro-ablative CO\textsubscript{2} laser seems to be effective in reducing symptoms related to vaginal atrophy. The effects of the treatment led to the recovery of a normal mucosal surface and function. The beneficial effects were reported after just the first session and were confirmed 2 months after the previous session. The treatment is quite comfortable and painless.

There are still many questions, for example, the long-term duration of this treatment. We have a maximum of 2 years follow-up experience, which is the same as that reported in previous studies.\textsuperscript{19,20}

Comparative studies between CO\textsubscript{2} laser treatment and vaginal use of topical estrogens are still lacking.

In conclusion, fractional micro-ablative CO\textsubscript{2} laser represents a valid treatment on VVA in postmenopausal women, but further studies are required to achieve a validated protocol and to evaluate the long-term efficacy.

Author Disclosure Statement

No competing financial interests exist.

References


Address correspondence to:
Ester Del Duca
Department of Dermatology
University of Rome Tor Vergata
Viale Oxford, 81
Rome 00133
Italy
E-mail: ester.delduca@gmail.com

Received: June 19, 2016.
Accepted after revision: August 20, 2016.
Published online: December 30, 2016.